Search results

Skip to results

Type

Status

Last updated

Showing 1 result for ribociclib - taken in addition with fulvestrant

  1. Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment (TA1036)

    Evidence-based recommendations on elacestrant (Korserdu) for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment in adults.

    Technology appraisal guidance
    Published
    5 February 2025
    View recommendations

    Sections for TA1036